🚀 VC round data is live in beta, check it out!
Synthaverse Valuation Multiples
Discover revenue and EBITDA valuation multiples for Synthaverse and similar public comparables like Adicet Bio, IBT, Citius Oncology, Nanexa and more.
Synthaverse Overview
About Synthaverse
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
Founded
1944
HQ
Employees
221
Website
Sectors
Financials (LTM)
EV
$102M
Synthaverse Financials
Synthaverse reported last 12-month revenue of $12M and EBITDA of $84K.
In the same LTM period, Synthaverse generated $84K in EBITDA and had net loss of ($4M).
Revenue (LTM)
Synthaverse P&L
In the most recent fiscal year, Synthaverse reported revenue of $20M and EBITDA of $4M.
Synthaverse expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12M | XXX | $20M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $12M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $84K | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | (31%) | XXX | 17% | XXX | XXX | XXX |
| Net Profit | ($4M) | XXX | $2M | XXX | XXX | XXX |
| Net Margin | (36%) | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $21M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Synthaverse Stock Performance
Synthaverse has current market cap of $79M, and enterprise value of $102M.
Market Cap Evolution
Synthaverse's stock price is $1.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $79M | 0.1% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynthaverse Valuation Multiples
Synthaverse trades at 8.7x EV/Revenue multiple, and 1213.8x EV/EBITDA.
EV / Revenue (LTM)
Synthaverse Financial Valuation Multiples
As of April 19, 2026, Synthaverse has market cap of $79M and EV of $102M.
Equity research analysts estimate Synthaverse's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synthaverse has a P/E ratio of (18.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79M | XXX | $79M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 1213.8x | XXX | 28.7x | XXX | XXX | XXX |
| EV/EBIT | (28.0x) | XXX | 29.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.3x | XXX | XXX | XXX |
| P/E | (18.7x) | XXX | 37.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 24.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Synthaverse Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Synthaverse Margins & Growth Rates
Synthaverse's revenue in the last fiscal year declined by (41%).
Synthaverse's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Synthaverse Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (41%) | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (98%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Synthaverse Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Synthaverse | XXX | XXX | XXX | XXX | XXX | XXX |
| Adicet Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| Citius Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanexa | XXX | XXX | XXX | XXX | XXX | XXX |
| Orexo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synthaverse M&A Activity
Synthaverse acquired XXX companies to date.
Last acquisition by Synthaverse was on XXXXXXXX, XXXXX. Synthaverse acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Synthaverse
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSynthaverse Investment Activity
Synthaverse invested in XXX companies to date.
Synthaverse made its latest investment on XXXXXXXX, XXXXX. Synthaverse invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Synthaverse
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Synthaverse
| When was Synthaverse founded? | Synthaverse was founded in 1944. |
| Where is Synthaverse headquartered? | Synthaverse is headquartered in Poland. |
| How many employees does Synthaverse have? | As of today, Synthaverse has over 221 employees. |
| Is Synthaverse publicly listed? | Yes, Synthaverse is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Synthaverse? | Synthaverse trades under SVE ticker. |
| When did Synthaverse go public? | Synthaverse went public in 2011. |
| Who are competitors of Synthaverse? | Synthaverse main competitors are Adicet Bio, IBT, Citius Oncology, Nanexa. |
| What is the current market cap of Synthaverse? | Synthaverse's current market cap is $79M. |
| What is the current revenue of Synthaverse? | Synthaverse's last 12 months revenue is $12M. |
| What is the current revenue growth of Synthaverse? | Synthaverse revenue growth (vs. last FY) is (41%). |
| What is the current EV/Revenue multiple of Synthaverse? | Current revenue multiple of Synthaverse is 8.7x. |
| Is Synthaverse profitable? | Yes, Synthaverse is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synthaverse? | Synthaverse's last 12 months EBITDA is $84K. |
| What is Synthaverse's EBITDA margin? | Synthaverse's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Synthaverse? | Current EBITDA multiple of Synthaverse is 1213.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.